Hualan Biological Vaccine Inc. (SHE:301207)
China · Delayed Price · Currency is CNY 19.17
+0.55 (2.95%)
At close: Mar 27, 2026
Hualan Biological Vaccine Revenue
In the year 2025, Hualan Biological Vaccine had annual revenue of 1.20B CNY with 6.62% growth. Hualan Biological Vaccine had revenue of 396.52M in the quarter ending December 31, 2025, with 132.63% growth.
Revenue
1.20B
Revenue Growth
+6.62%
P/S Ratio
9.49
Revenue / Employee
1.61M
Employees
748
Market Cap
11.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20B | 74.69M | 6.62% |
| Dec 31, 2024 | 1.13B | -1.28B | -53.21% |
| Dec 31, 2023 | 2.41B | 584.79M | 32.03% |
| Jan 1, 2023 | 1.83B | -4.17M | -0.23% |
| Jan 1, 2022 | 1.83B | -596.52M | -24.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Chengzhi | 11.53B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Aurisco Pharmaceutical | 1.62B |
| Liaoning Chengda Biotechnology | 1.39B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Jiangxi Fushine Pharmaceutical | 1.18B |